Malaria is a parasitic infection that can become severe and lead to a patient’s death, besides having records of resistance to treatment and only a few options to treat it, generating the need for more research on new antimalarial compounds. The present study aimed at evaluating the antiplasmodial activity of two synthetic compounds, through in vitro assays, and ex vivo assays. The in vitro studies demonstrated that the synthetic molecules presented inhibitory concentrations for 50% of the parasite population (IC50) of 4.4 and 6.3 µM against sensitive and resistant strains, respectively. Compound 3RJ was observed to act in the first 8h against young trophozoites. Regarding the ex vivo study, 3RJ didn’t behave similarly to the reference drug, but remained effective against the circulating strains of P. falciparum in the state of Rondônia, Brazil. The results observed demonstrate that these triazole-based compounds are promising candidates in the development of antimalarial drugs.